Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3180689 | 0.91 | L3MBTL1 (0.61) | GAAL3MBTL1NAMPTNPSR1CA1 | |
| SCHEMBL16192930 | 0.90 | GAA (0.61) | GAAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL12133145 | 0.89 | GAA (0.60) | GAAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL3284231 | 0.87 | GAA (0.56) | GAAL3MBTL1NAMPTNPSR1CA1 | |
| SCHEMBL1724201 | 0.86 | GAA (0.60) | GAAMEN1KMT2ACYP2C19CYP1A2 | |
| SCHEMBL24011136 | 0.85 | GAA (0.58) | GAAMEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL5796279 | 0.85 | L3MBTL1 (0.56) | GAAMEN1KMT2ACYP2C19L3MBTL1 | |
| SCHEMBL15259134 | 0.85 | L3MBTL1 (0.56) | GAAKMT2AL3MBTL1NAMPTNPSR1 | |
| SCHEMBL1164796 | 0.85 | L3MBTL1 (0.56) | GAAL3MBTL1NAMPTNPSR1CA1 | |
| SCHEMBL12685839 | 0.85 | L3MBTL1 (0.56) | GAAL3MBTL1NAMPTNPSR1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106674080-A | Synthesis method of panobinostat | 南京卡文迪许生物工程技术有限公司 | 2017-05-17 | — | — | CN | claimed |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| CN-115572252-B | Isoindolinone inhibitors of MDM2-P53 interaction with anticancer activity | 阿斯泰克斯治疗有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2024-08-27 | — | — | US | disclosed |
| EP-4151633-A1 | INTERMEDIATES OF ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | Astex Therapeutics Limited (GB) | 2023-03-22 | — | — | EP | disclosed |
| CN-115572252-A | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2023-01-06 | — | — | CN | disclosed |
| EP-3356350-B1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LTD (GB) | 2022-11-16 | — | — | EP | disclosed |
| CN-108290871-B | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-01-17 | — | — | US | disclosed |
| WO-2019006422-A1 | CORE-TO-SURFACE POLYMERIZATION FOR THE SYNTHESIS OF STAR POLYMERS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-01-03 | — | — | WO | disclosed |
| EP-3356350-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | Astex Therapeutics Limited (GB) | 2018-08-08 | — | — | EP | disclosed |
| CN-108368101-A | SELECTIVE NR2B ANTAGONISTS | 百时美施贵宝公司 | 2018-08-03 | — | — | CN | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-6878736-B1 | Histamine H3 receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| EP-1056733-B1 | HISTAMINE H3 RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2004-01-07 | — | — | EP | disclosed |
| EP-1056733-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999042458-A1 | HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12071429-B2 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | GAA 2315/4885MEN1 1609/4885KMT2A 3047/4885 |
| US-20250092027-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | GAA 2342/4885MEN1 1624/4885KMT2A 3084/4885 |
| US-20190016708-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | GAA 2315/4885MEN1 1609/4885KMT2A 3047/4885 |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR1A, HTR2A | GAA 4045/4885MEN1 4387/4885KMT2A 1221/4885 |
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | GAA 2315/4885MEN1 1609/4885KMT2A 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.